{
  "success": true,
  "pagesUsed": [
    2,
    3,
    4,
    5,
    6,
    7,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    19,
    20,
    21,
    22,
    24,
    25,
    26,
    27,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "ALXN1840",
        "type": {
          "id": "4a645177-85c4-43e1-baa0-ea3a67900b52",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "5260bc4d-1eda-478b-a0be-94e746bbd10f",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "A novel copper binding agent (bis-choline tetrathiomolybdate) in development for the treatment of Wilson disease.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Copper-chelating therapies",
        "type": {
          "id": "f604bb09-86fa-42a8-9875-5821b2d70293",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "0dfc49a2-c8b8-4d3d-a123-5d7c2c6a89fd",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Penicillamine or trientine; must be discontinued starting on Day -4.",
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Zinc therapy",
        "type": {
          "id": "b970e824-d621-4a5c-a593-9bd1746991e7",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "33ed8526-298a-4793-a15b-ec7ca910b8f0",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Must be discontinued for a minimum of 21 days prior to Day 1.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Paracetamol/acetaminophen",
        "type": {
          "id": "37fecdd8-b22b-4037-8bb7-01f8fb637882",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "a53fbdba-03c6-461c-808e-77460080473d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted for use with Investigator approval, limited to a maximum of 1000 mg per day."
      },
      {
        "id": "int_5",
        "name": "Ibuprofen",
        "type": {
          "id": "5f1d4dd5-bb57-4ff8-b9cf-b9b7c1996a5c",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "4fa5c77f-eecb-44ed-9658-290900cf2acb",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted with caution; dose must not exceed 1200 mg in any 24-hour period."
      },
      {
        "id": "int_6",
        "name": "St John’s wort",
        "type": {
          "id": "0180a8da-48e7-49a3-b808-e55dccd56a64",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "dc07665c-d36a-4962-9266-f5851e6510ea",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited; must be discontinued at least 2 weeks before the first study intervention."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "ALXN1840 tablets",
        "administrableDoseForm": {
          "id": "9386e8a0-290e-4130-9659-e20d0caada8e",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "336ce5ee-8feb-4f50-abbd-d3623b70e499",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "5770601c-81a5-49c1-a6ab-4cd966cc00dd",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "15 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Alexion Pharmaceuticals"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "ALXN1840 15 mg daily",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Approximately 28 days (Day 1 through Day 28)"
      },
      {
        "id": "admin_2",
        "name": "ALXN1840 30 mg daily",
        "instanceType": "Administration",
        "dose": "30 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "11 days (Day 29 through Day 39)"
      },
      {
        "id": "admin_3",
        "name": "ALXN1840 15 mg QOD",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "every other day",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "As specified in dose modification/rechallenge protocols"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "bis-choline tetrathiomolybdate",
        "instanceType": "Substance",
        "description": "Active drug moiety; formerly known as WTX101"
      },
      {
        "id": "sub_2",
        "name": "tetrathiomolybdic acid",
        "instanceType": "Substance",
        "description": "Active component (7.8 mg per 15 mg tablet)"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 6,
      "productCount": 1,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "ALXN1840",
        "role": "Investigational Product",
        "description": "A novel copper binding agent (bis-choline tetrathiomolybdate) in development for the treatment of Wilson disease."
      },
      {
        "name": "Copper-chelating therapies",
        "role": "Prior Medication",
        "description": "Penicillamine or trientine; must be discontinued starting on Day -4."
      },
      {
        "name": "Zinc therapy",
        "role": "Prior Medication",
        "description": "Must be discontinued for a minimum of 21 days prior to Day 1."
      },
      {
        "name": "Paracetamol/acetaminophen",
        "role": "Concomitant Medication",
        "description": "Permitted for use with Investigator approval, limited to a maximum of 1000 mg per day."
      },
      {
        "name": "Ibuprofen",
        "role": "Concomitant Medication",
        "description": "Permitted with caution; dose must not exceed 1200 mg in any 24-hour period."
      },
      {
        "name": "St John’s wort",
        "role": "Concomitant Medication",
        "description": "Prohibited; must be discontinued at least 2 weeks before the first study intervention."
      }
    ],
    "products": [
      {
        "name": "ALXN1840 tablets",
        "doseForm": "Tablet",
        "strength": "15 mg",
        "manufacturer": "Alexion Pharmaceuticals"
      }
    ],
    "substances": [
      {
        "name": "bis-choline tetrathiomolybdate",
        "description": "Active drug moiety; formerly known as WTX101"
      },
      {
        "name": "tetrathiomolybdic acid",
        "description": "Active component (7.8 mg per 15 mg tablet)"
      }
    ],
    "administrations": [
      {
        "name": "ALXN1840 15 mg daily",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Approximately 28 days (Day 1 through Day 28)"
      },
      {
        "name": "ALXN1840 30 mg daily",
        "dose": "30 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "11 days (Day 29 through Day 39)"
      },
      {
        "name": "ALXN1840 15 mg QOD",
        "dose": "15 mg",
        "frequency": "every other day",
        "route": "Oral",
        "duration": "As specified in dose modification/rechallenge protocols"
      }
    ],
    "devices": []
  }
}